Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 321,755 Intuitive Surgical, Inc. (NASDAQ:ISRG)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 321,755 shares of the medical equipment provider's stock, valued at approximately $167,943,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.09% of Intuitive Surgical at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Sycomore Asset Management lifted its stake in Intuitive Surgical by 27.4% in the 4th quarter. Sycomore Asset Management now owns 18,945 shares of the medical equipment provider's stock worth $9,214,000 after purchasing an additional 4,079 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Intuitive Surgical by 5.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,843 shares of the medical equipment provider's stock worth $5,138,000 after purchasing an additional 525 shares in the last quarter. Castleark Management LLC raised its position in shares of Intuitive Surgical by 3.4% during the 4th quarter. Castleark Management LLC now owns 90,469 shares of the medical equipment provider's stock valued at $47,221,000 after buying an additional 2,990 shares during the period. Truist Financial Corp raised its position in shares of Intuitive Surgical by 3.0% during the 4th quarter. Truist Financial Corp now owns 248,092 shares of the medical equipment provider's stock valued at $129,494,000 after buying an additional 7,298 shares during the period. Finally, Global X Japan Co. Ltd. raised its position in shares of Intuitive Surgical by 9.8% during the 4th quarter. Global X Japan Co. Ltd. now owns 46,289 shares of the medical equipment provider's stock valued at $24,161,000 after buying an additional 4,140 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Intuitive Surgical

In related news, EVP Robert Desantis sold 188 shares of the business's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $515.91, for a total value of $96,991.08. Following the transaction, the executive vice president now owns 5,224 shares in the company, valued at $2,695,113.84. The trade was a 3.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jami K. Nachtsheim sold 2,400 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $520.00, for a total value of $1,248,000.00. Following the completion of the transaction, the director now owns 6,371 shares in the company, valued at $3,312,920. This trade represents a 27.36% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,111 shares of company stock worth $15,364,055. Corporate insiders own 0.70% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on ISRG. Truist Financial reduced their price target on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Piper Sandler reduced their price target on shares of Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 23rd. Robert W. Baird reduced their price target on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 23rd. Barclays reduced their price target on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. Finally, Evercore ISI reduced their price target on shares of Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating on the stock in a research report on Wednesday, April 23rd. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $596.05.

Intuitive Surgical Stock Down 0.8%

Intuitive Surgical stock traded down $4.61 during midday trading on Friday, reaching $551.14. The company's stock had a trading volume of 2,091,011 shares, compared to its average volume of 1,647,905. Intuitive Surgical, Inc. has a fifty-two week low of $396.48 and a fifty-two week high of $616.00. The company has a market cap of $197.54 billion, a P/E ratio of 85.98, a P/E/G ratio of 5.85 and a beta of 1.70. The business has a 50-day simple moving average of $516.44 and a 200-day simple moving average of $538.53.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.55% and a net margin of 27.81%. The business had revenue of $2.25 billion for the quarter, compared to analysts' expectations of $2.19 billion. During the same quarter in the previous year, the firm earned $1.50 earnings per share. As a group, equities analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.